汤臣倍健公司内部正在经历一场大变革,这反映在保健品竞争和变局上的“硝烟”四起。

2023-08-30 18:01:00 汤臣倍健股份有限公司

• 汤臣倍健半年报:内部变革初见成效 but external competition remains fierce Recently, China's leading nutrition保健品 company,汤臣倍健(300146.SZ), has submitted its half-yearly report for 2023. In the first half of this year, the company's营业收入 and归属于上市公司股东的净利润分别为 55.96 billion yuan and 15.45 billion yuan, an increase of 32.58% and 47.41% respectively compared to the same period in the previous year. It is worth noting that in response to the company's performance in 2022, the实际控制人 Liang Yunbao expressed dissatisfaction and launched internal structural adjustments. The company's performance has returned to growth, but the external competition is still fierce. These external opponents mainly come from international brands. Among them, the rising star in the Chinese market,健合国际(01112.HK), has become the company's largest competitive peer. In the first half of this year, China's revenue from健合国际 was 50.76 billion yuan. The current battle for market share in the supplement industry is far from over. 01 The "new tricks" of the sales division 汤臣倍健的内部

  

• 招聘范围主要集中在广州、珠海、上海，主要招聘经验要求为3-5年，学历要求为本科的岗位。

• 公司参与招标21次，公司参与中标5次，中标金额为300.00（万元），最近项目为：汤臣倍健股份有限公司建设工程项目（接待办公中心）规划条件核实批后公告、汤臣倍健股份有限公司建设工程项目（成品输送线扩建）规划条件核实批后公告、汤臣倍健股份有限公司建设工程项目（接待办公中心）规划条件核实批前公示。